Treatment failure with new hepatitis C drugs

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 3, 2012, Pages 313-323

  Soriano, Vincent ^a   Vispo, Eugenia ^a   Poveda, Eva ^a   Labarga, Pablo ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Boceprevir; DAA; Drug resistance; HCV; HIV; Telaprevir

Indexed keywords

ABT 072; ABT 333; ABT 450; ANTIVIRUS AGENT; BI 1335; BI 7127; BMS 65032; BOCEPREVIR; DACLATASVIR; DANOPREVIR; FILIBUVIR; GS 9256; GS 9526; IDX 184; IDX 320; MERICITABINE; MK 5172; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; PSI 7851; PSI 7977; PSI 938; RIBAVIRIN; SIMEPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VCH 759; VHC 759; VX 222;

ANEMIA; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSGEUSIA; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; PHENOTYPE; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT FAILURE;

EID: 84856304724     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.653341     Document Type: Review

References (54)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
2. McHutchison J, Lawitz E, Shiffman M, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
3. Hadziyannis S, Sette H, Morgan T, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
4. Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
5. Bacon B, Gordon S, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
6. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
7. Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
8. Soriano V, Vispo E, Poveda E, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011;66:1673-86.
9. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89 (Pubitemid 46763278)
10. Martinez S, Crespo G, Navasa M, Forns X. Non-invasive assessment of liver fibrosis. Hepatology 2011;53:325-35
11. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
12. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
13. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4
14. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45
15. Rallon N, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-9.
16. Jensen D. A new era of hepatitis C therapy begins. N Engl J Med 2011;364:1272-4
17. Pawlotsky JM, Chevaliez S, McHutchison J. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98 (Pubitemid 46695724)
18. Trevino A, de Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against hepatitis C virus (HCV) in newly diagnosed HIV/HCV-coinfected patients in Spain. Antivir Ther 2011;16:413-16
19. Coelmont L, Hanoulle X, Chatterji U, et al. DEB-025 (alisporivir) inhibits HCV replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 2010;5:e13687
20. Sherman K, Flamm S, Afdhal N, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24
21. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68
22. Lo Re III V, Teal V, Localio R, et al. Relationship between adherence to HCV therapy and virologic outcomes: a cohort study. Ann Intern Med 2011;155:353-60
23. Weiss J, Alcorn M, Rabkin J, Dieterich D. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol 2012; In press
24. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. AIDS 2011;25:2197-208.
25. Seden K, Back D, Shoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-85
26. Poveda E, Vispo E, Barreiro P, et al. Predicted challenges using direct acting antivirals in the current HIV-HCV coinfected population in Spain. Antivir Ther 2012; In press
27. Guedj J, Perelson A. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011;53:1801-8
28. Ruiz-Jarabo C, Arias A, Molina-Paris C, et al. Duration and fitness dependence of quasispecies memory. J Mol Biol 2002;315:285-96 (Pubitemid 34729340)
29. Soriano V, Perelson A, Zoulim F. Why different dynamics of selection of drug resistance in HIV, hepatitis B and C viruses? J Antimicrob Chemother 2008;62:1-4 (Pubitemid 351865869)
30. Sarrazin C, Kieffer T, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77 (Pubitemid 46677938)
31. McCown M, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52:1604-12 (Pubitemid 351614649)
32. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-62.
33. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011;55:192-206
34. Kieffer T, Kwong A, Picchio G. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010;65:202-12
35. Bae A, Sun S, Qi X, et al. Susceptibility of treatment-naive HCV clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010;54:5288-97
36. Ludmerer S, Graham D, Boots E, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005;49:2059-69 (Pubitemid 40631625)
37. McCown M, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009;53:2129-32
38. Soriano V, Peters M, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009;48:313-20
39. Bartels D, Zhou Y, Zhang E, et al. Natural prevalence of HCV variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008;198:800-7
40. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008;48:1769-78
41. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 2009;49:1069-82
42. Sun S, Bae A, Qi X, et al. Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naive HCV patient isolates. J Viral Hepat 2011;18:861-70
43. Trimoulet P, Belzunce C, Faure M, et al. HCV protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med 2011;12:506-9
44. Plaza Z, Soriano V, Gonzalez MM, et al. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. J Antimicrob Chemother 2011;66:2838-42
45. Gao M, Nettles R, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100
46. Scheel T, Gottwein J, Mikkelsen L, et al. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 2011;140:1032-42
47. McPhee F, Hernandez D, Yu F, et al. Characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052. In: Abstracts of the 46th EASL Annual Meeting, Berlin, Germany, 2011. Abstract. 63. J Hepatol 2011;54(Suppl 1): 28-9
48. Plaza Z, Soriano V, Vispo E, et al. Prevalence of natural polymorphisms at the Hepatitis C virus NS5A gene associated with resistance to BMS-052, a NS5A inhibitor. Antivir Ther 2012; In press
49. Manns M, Bourliere M, Benhamou Y, et al. Potency, safety and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype 1 infection. J Hepatol 2011;54:1114-22
50. Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG1728) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
51. Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: Week 12 interim results of the SOUND-C2 study. Hepatology 2011;54(Suppl): 1436 [LB-15
52. McPhee F, Hernandez D, Yu F, et al. characterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor 790052. J Hepatol 2011;54(Suppl 1):28-9
53. Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV-RNA < LOD at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). In: Abstracts of the 46th EASL Annual Meeting, Berlin, Germany, 2011 [abstract 1370]. J Hepatol 2011;54(Suppl 1):543
54. Forton D. Hepatitis C treatment -clearing the mind. J Hepatol 2012; In press